Visfatin and Adiponectin Have an Opposite Correlation with Inflammation and Metabolic Syndrome in Non-Diabetic Obese Indonesian Men

Anna Meiliana, Gatot Susilo Lawrence, Ilhamjaya Patellongi, Andi Wijaya, Suryani As'ad

Abstract


BACKGROUND: Along with the increase in obesity is a parallel increase in the prevalence of metabolic complications of obesity, often referred to as the metabolic syndrome (MetS). The role of adipose tissue in MetS has continued to evolve with the description of numerous secretory peptides from adipocytes named adipocytokines or adipokines. Recent studies have found visfatin as the regulation of inflammatory and immunomodulating prosesses, meanwhile adiponectin was known to have a potent anti-inflammatory properties. Here we try to assess the correlation between those two adipokines to MetS, via an inflammatory pathway.

METHODS: This was a cross-sectional study on 128 non diabetic obese male subject (waist circumferences ≥90 cm). Visfatin and adiponectin were assessed by ELISA. Statistical analysis was performed using SPSS for Windows v.16.00 with signifcantly p<0.05. The correlations among biomarkers were assessed using Spearman's Rho test.

RESULTS: This study showed a significant positive correlation between levels of visfatin and inflammatory markers TNF-α (r=0.22, p<0.005), and hsCRP (r=0.12, p=0.19), significant negative correlation between levels of adiponectin and TNF-α (r=-0.22-8, p<0.005-1), adiponectin and hsCRP (r=-0.14, p=0.11) and visfatin (r=-0.029, p<0.01). Plasma visfatin levels were increased along with the number MetS components, white plasma adiponectin showed inversely relation.

CONCLUSION: Our present study has shown that visfatin has a proinflammatory properties and adiponectin has an anti-inflammatory properties, and how they have an opposite effects on MetS. Visfatin was found to have a positive correlaton while adiponectin was found to have a negative correlation with the number of MetS components.

KEYWORDS: Obesity, Inflammation, Metabolic Syndrome, Adipocytokines, Visfatin, Adiponectin, TNF-α, hsCRP


Full Text:

PDF

References


Rasouli N, Kern PA. Adipocytokines and the metabolic complications of obesity. J Clin Endocrinol Metab. 2008; 93 (11 Suppl 1): S64-73, CrossRef.

Alberti KGM, Zimmet P, Shaw J. The metabolic syndrome - a new worldwide definition. Lancet. 2005; 366: 1059-62, CrossRef.

Wozniak SE, Gee LL, Wachtel MS, Frezza EE. Adipose tissue: the new endocrine organ? A review article. Dig Dis Sci. 2008; 54: 1847-56, CrossRef.

Lee WJ, Wu CS, Lin H, Lee IT, Wu CM, Tseng JJ, et al. Visfatin-induced expression of inflammatory mediators in human endothelial cells through the NF-κB pathway. Int J Obes. 2009; 33: 465-72, CrossRef.

Körner A, Garten A, Blüher M, Tauscher R, Kratzsch J, Kiess W. Molecular characteristics of serum visfatin and differential detection by immunoassays. J Clin Endocrinol Metab. 2007; 92: 4783-91, CrossRef.

Fukuhara A, Matsuda M, Nishizawa M, Segawa K, Tanaka M, Kishimoto K, et al. Visfatin: A protein secreted by visceral fat that mimics the effects of insulin. Science. 2005; 307: 426-30, CrossRef.

Moschen AR, Kaser A, Enrich B, Mosheimer B, Theurl M, Niederegger H, et al. Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. J Immunol. 2007; 178: 1748-58, CrossRef.

Schraw T, Wang ZV, Halberg N, Hawkins M, Scherer PE. Plasma adiponectin complexes have distinct biochemical characteristics. Endocrinology. 2008; 149: 2270-82, CrossRef.

Maury E, Brichard SM. Adipokine dysregulation, adipose tissue inflammation and metabolic syndrome. Mol Cell Endocrinol. 2010; 314: 1-16, CrossRef.

Park PH, Huang H, McMullen MR, Mandal P, Sun L, Nagy LE. Suppression of lipopolysaccharide-stimulated tumor necrosis factor - Production by adiponectin is mediated by transcriptional and post-transcriptional mechanisms. J Biol Chem. 2008; 283: 26850-8, CrossRef.

Trayhurn P, Wood IS. Adipokines: inflammation and the pleiotropic role of white adipose tissue. Br J Nutr. 2004; 92: 347, CrossRef.

Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J Clin Invest. 2003; 111: 1805-12, CrossRef.

Clyne B, Olshaker JS. The C-reactive protein. J Emerg Med. 1999; 17: 1019-25, CrossRef.

Ibáñez L, Sebastiani G, Lopez-Bermejo A, Díaz M, Gómez-Roig MD, de Zegher F. Gender specificity of body adiposity and circulating adiponectin, visfatin, insulin, and insulin growth factor-I at term birth: relation to prenatal growth. J Clin Endocrinol Metab. 2008; 93: 2774-8, CrossRef.

Filippatos TD, Derdemezis CS, Gazi IF, Lagos K, Kiortsis DN, Tselepis AD, et al. Increased plasma visfatin levels in subjects with the metabolic syndrome. Eur J Clin Invest. 2007; 38: 71-2, CrossRef.

Zhang P, Wang Y, Fan Y, Tang Z, Wang N. Overexpression of adiponectin receptors potentiates the antiinflammatory action of subeffective dose of globular adiponectin in vascular endothelial cells. Arterioscler, Thromb, Vasc Biol. 2008; 29: 67-74, CrossRef.

Ouchi N, Walsh K. A novel role for adiponectin in the regulation of inflammation. Arterioscler, Thromb Vasc Biol. 2008; 28:1 219-21, CrossRef.

Xydakis AM, Case CC, Jones PH, Hoogeveen RC, Liu M-Y, Smith EO, et al. Adiponectin, inflammation, and the expression of the metabolic syndrome in obese individuals: the impact of rapid weight loss through caloric restriction. The Journal of Clinical Endocrinology & Metabolism. 2004; 89: 2697-703, CrossRef.




DOI: https://doi.org/10.18585/inabj.v1i3.104

Copyright (c) 2009 The Prodia Education and Research Institute

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

 

Indexed by:

                  

               

                

 

 

The Prodia Education and Research Institute